RATIONALE: Although the rate of annual decline in FEV1 is one of the most important outcome measures in chronic obstructive pulmonary disease (COPD), little is known about intersubject variability based on clinical phenotypes. OBJECTIVES: To examine the intersubject variability in a 5-year observational cohort study, particularly focusing on emphysema severity. METHODS: A total of 279 eligible patients with COPD (stages I-IV: 26, 45, 24, and 5%) participated. We conducted a detailed assessment of pulmonary function and computed tomography (CT) at baseline, and performed spirometry every 6 months before and after inhalation of bronchodilator. Smoking status, exacerbation, and pharmacotherapy were carefully monitored. Emphysema severity was evaluated by CT and annual measurements of carbon monoxide transfer coefficient. MEASUREMENTS AND MAIN RESULTS: Using mixed effects model analysis, the annual decline in post-bronchodilator FEV1 was -32±24 (SD) ml/yr (n=261). We classified the subjects of less than the 25th percentile as Rapid decliners, the 25th to 75th percentile as Slow decliners, and greater than the 75th percentile as Sustainers (-63±2, -31±1, and -2±1 [SE] ml/yr). Emphysema severity, but not %FEV1, showed significant differences among the three groups. Multiple logistic regression analysis demonstrated that the Rapid decliners were independently associated with emphysema severity assessed either by CT or carbon monoxide transfer coefficient. The Sustainers displayed less emphysema and higher levels of circulating eosinophils. CONCLUSIONS: Emphysema severity is independently associated with a rapid annual decline in FEV1 in COPD. Sustainers and Rapid decliners warrant specific attention in clinical practice.
RATIONALE: Although the rate of annual decline in FEV1 is one of the most important outcome measures in chronic obstructive pulmonary disease (COPD), little is known about intersubject variability based on clinical phenotypes. OBJECTIVES: To examine the intersubject variability in a 5-year observational cohort study, particularly focusing on emphysema severity. METHODS: A total of 279 eligible patients with COPD (stages I-IV: 26, 45, 24, and 5%) participated. We conducted a detailed assessment of pulmonary function and computed tomography (CT) at baseline, and performed spirometry every 6 months before and after inhalation of bronchodilator. Smoking status, exacerbation, and pharmacotherapy were carefully monitored. Emphysema severity was evaluated by CT and annual measurements of carbon monoxide transfer coefficient. MEASUREMENTS AND MAIN RESULTS: Using mixed effects model analysis, the annual decline in post-bronchodilator FEV1 was -32±24 (SD) ml/yr (n=261). We classified the subjects of less than the 25th percentile as Rapid decliners, the 25th to 75th percentile as Slow decliners, and greater than the 75th percentile as Sustainers (-63±2, -31±1, and -2±1 [SE] ml/yr). Emphysema severity, but not %FEV1, showed significant differences among the three groups. Multiple logistic regression analysis demonstrated that the Rapid decliners were independently associated with emphysema severity assessed either by CT or carbon monoxide transfer coefficient. The Sustainers displayed less emphysema and higher levels of circulating eosinophils. CONCLUSIONS:Emphysema severity is independently associated with a rapid annual decline in FEV1 in COPD. Sustainers and Rapid decliners warrant specific attention in clinical practice.
Authors: Ming Shan; Ran You; Xiaoyi Yuan; Michael V Frazier; Paul Porter; Alexander Seryshev; Jeong-Soo Hong; Li-zhen Song; Yiqun Zhang; Susan Hilsenbeck; Lawrence Whitehead; Nazanin Zarinkamar; Sarah Perusich; David B Corry; Farrah Kheradmand Journal: J Clin Invest Date: 2014-02-24 Impact factor: 14.808
Authors: Wassim W Labaki; Carlos H Martinez; Fernando J Martinez; Craig J Galbán; Brian D Ross; George R Washko; R Graham Barr; Elizabeth A Regan; Harvey O Coxson; Eric A Hoffman; John D Newell; Douglas Curran-Everett; James C Hogg; James D Crapo; David A Lynch; Ella A Kazerooni; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Michael H Cho; Peter J Castaldi; Craig P Hersh; Brian D Hobbs; R Graham Barr; Ruth Tal-Singer; Per Bakke; Amund Gulsvik; Raúl San José Estépar; Edwin J R Van Beek; Harvey O Coxson; David A Lynch; George R Washko; Nan M Laird; James D Crapo; Terri H Beaty; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Paul A Reyfman; George R Washko; Mark T Dransfield; Avrum Spira; MeiLan K Han; Ravi Kalhan Journal: Am J Respir Crit Care Med Date: 2018-08-15 Impact factor: 21.405
Authors: George R Washko; Gregory L Kinney; James C Ross; Raúl San José Estépar; MeiLan K Han; Mark T Dransfield; Victor Kim; Hiroto Hatabu; Carolyn E Come; Russell P Bowler; Edwin K Silverman; James Crapo; David A Lynch; John Hokanson; Alejandro A Diaz Journal: Acad Radiol Date: 2016-12-08 Impact factor: 3.173
Authors: Jae Seung Lee; Seon Ok Kim; Joon Beom Seo; Ji-Hyun Lee; Eun Kyung Kim; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Sei Won Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee Journal: Lung Date: 2013-05-29 Impact factor: 2.584
Authors: Yael Strulovici-Barel; Michelle R Staudt; Anja Krause; Cynthia Gordon; Ann E Tilley; Ben-Gary Harvey; Robert J Kaner; Charleen Hollmann; Jason G Mezey; Hans Bitter; Sreekumar G Pillai; Holly Hilton; Gerhard Wolff; Christopher S Stevenson; Sudha Visvanathan; Jay S Fine; Ronald G Crystal Journal: Thorax Date: 2016-07-26 Impact factor: 9.139